World's Best Scientists 2026 revealed!

D-Index & Metrics

Medicine

D-Index
99
Citations
35749
World Ranking
8602
National Ranking
4432

Stephen D. Nimer publication distribution in Medicine in 2026

The chart shows the distribution of publications by all Research.com ranked scientists in the field of Medicine in 2026. The highlighted bar marks where Stephen D. Nimer sits on this spectrum.

101–120 publications: 5 scientists 121–140 publications: 26 scientists 141–160 publications: 73 scientists 161–180 publications: 155 scientists 181–200 publications: 230 scientists 201–220 publications: 363 scientists 221–240 publications: 487 scientists 241–260 publications: 545 scientists 261–280 publications: 722 scientists 281–300 publications: 768 scientists 301–320 publications: 834 scientists 321–340 publications: 895 scientists 341–360 publications: 922 scientists 361–380 publications: 838 scientists 381–400 publications: 861 scientists 401–420 publications: 918 scientists 421–440 publications: 806 scientists 441–460 publications: 771 scientists 461–480 publications: 751 scientists 481–500 publications: 713 scientists 501–520 publications: 617 scientists 521–540 publications: 610 scientists 541–560 publications: 537 scientists 561–580 publications: 504 scientists 581–600 publications: 509 scientists 601–620 publications: 396 scientists 621–640 publications: 386 scientists 641–660 publications: 371 scientists 661–680 publications: 340 scientists 681–700 publications: 336 scientists 701–720 publications: 307 scientists 721–740 publications: 259 scientists 741–760 publications: 230 scientists 761–780 publications: 228 scientists 781–800 publications: 217 scientists 801–820 publications: 204 scientists 821–840 publications: 186 scientists 841–860 publications: 177 scientists 861–880 publications: 155 scientists 881–900 publications: 139 scientists 901–920 publications: 145 scientists 921–940 publications: 116 scientists 941–960 publications: 133 scientists 961–980 publications: 91 scientists 981–1,000 publications: 96 scientists 1,001–1,020 publications: 77 scientists 1,021–1,040 publications: 70 scientists 1,041–1,060 publications: 63 scientists 1,061–1,080 publications: 77 scientists 1,081–1,100 publications: 49 scientists 1,101–1,120 publications: 54 scientists 1,121–1,140 publications: 49 scientists 1,141–1,160 publications: 51 scientists 1,161–1,180 publications: 35 scientists 1,181–1,200 publications: 39 scientists 1,201–1,220 publications: 26 scientists 1,221–1,240 publications: 37 scientists 1,241–1,260 publications: 36 scientists 1,261–1,280 publications: 27 scientists 1,281–1,300 publications: 32 scientists 1,301–1,320 publications: 28 scientists 1,321–1,340 publications: 17 scientists 1,341–1,360 publications: 30 scientists 1,361–1,380 publications: 28 scientists 1,381–1,400 publications: 17 scientists 1,401–1,420 publications: 21 scientists 1,421–1,440 publications: 15 scientists 1,441–1,460 publications: 12 scientists 1,461–1,480 publications: 12 scientists 1,481–1,500 publications: 18 scientists 1,501–1,520 publications: 14 scientists 1,521–1,540 publications: 17 scientists 1,541–1,560 publications: 15 scientists 1,561–1,580 publications: 6 scientists 1,581–1,600 publications: 2 scientists 1,601–1,620 publications: 12 scientists 1,621–1,640 publications: 11 scientists 1,641–1,660 publications: 8 scientists 1,661–1,680 publications: 5 scientists 1,681–1,700 publications: 5 scientists 1,701–1,720 publications: 10 scientists 1,721–1,740 publications: 12 scientists 1,741–1,760 publications: 14 scientists 1,761–1,780 publications: 6 scientists 1,781–1,795 publications: 5 scientists 1,796+ publications: 100 scientists
101 publications 1,796+

This scientist: 465 publications — 52nd percentile

52% of scientists in this discipline score the same or lower.

The last bar groups every scientist with 1,796 publications or more.

Stephen D. Nimer D-index placement in Medicine in 2026

The chart shows the D-index (discipline H-index) distribution of Medicine scientists ranked by Research.com in 2026. The highlighted bar marks where Stephen D. Nimer sits on this spectrum.

70–71 D-Index: 226 scientists 72–73 D-Index: 391 scientists 74–75 D-Index: 574 scientists 76–77 D-Index: 730 scientists 78–79 D-Index: 891 scientists 80–81 D-Index: 972 scientists 82–83 D-Index: 1,027 scientists 84–85 D-Index: 1,003 scientists 86–87 D-Index: 960 scientists 88–89 D-Index: 970 scientists 90–91 D-Index: 922 scientists 92–93 D-Index: 839 scientists 94–95 D-Index: 808 scientists 96–97 D-Index: 779 scientists 98–99 D-Index: 668 scientists 100–101 D-Index: 611 scientists 102–103 D-Index: 630 scientists 104–105 D-Index: 513 scientists 106–107 D-Index: 541 scientists 108–109 D-Index: 445 scientists 110–111 D-Index: 429 scientists 112–113 D-Index: 399 scientists 114–115 D-Index: 393 scientists 116–117 D-Index: 318 scientists 118–119 D-Index: 302 scientists 120–121 D-Index: 287 scientists 122–123 D-Index: 255 scientists 124–125 D-Index: 256 scientists 126–127 D-Index: 252 scientists 128–129 D-Index: 230 scientists 130–131 D-Index: 179 scientists 132–133 D-Index: 168 scientists 134–135 D-Index: 163 scientists 136–137 D-Index: 159 scientists 138–139 D-Index: 134 scientists 140–141 D-Index: 134 scientists 142–143 D-Index: 118 scientists 144–145 D-Index: 109 scientists 146–147 D-Index: 106 scientists 148–149 D-Index: 74 scientists 150–151 D-Index: 79 scientists 152–153 D-Index: 80 scientists 154–155 D-Index: 87 scientists 156–157 D-Index: 57 scientists 158–159 D-Index: 74 scientists 160–161 D-Index: 69 scientists 162–163 D-Index: 60 scientists 164–165 D-Index: 53 scientists 166–167 D-Index: 39 scientists 168–169 D-Index: 42 scientists 170–171 D-Index: 32 scientists 172–173 D-Index: 39 scientists 174–175 D-Index: 40 scientists 176–177 D-Index: 28 scientists 178–179 D-Index: 19 scientists 180–181 D-Index: 23 scientists 182–183 D-Index: 31 scientists 184–185 D-Index: 18 scientists 186–187 D-Index: 20 scientists 188–189 D-Index: 22 scientists 190–191 D-Index: 13 scientists 192–193 D-Index: 21 scientists 194–195 D-Index: 12 scientists 196–197 D-Index: 12 scientists 198–199 D-Index: 14 scientists 200–201 D-Index: 15 scientists 202–203 D-Index: 13 scientists 204–205 D-Index: 10 scientists 206–207 D-Index: 8 scientists 208–209 D-Index: 4 scientists 210–211 D-Index: 12 scientists 212–213 D-Index: 11 scientists 214–215 D-Index: 10 scientists 216 D-Index: 4 scientists 217+ D-Index: 98 scientists
70 D-Index 217+

This scientist: 99 D-Index — 58th percentile

58% of scientists in this discipline score the same or lower.

The last bar groups every scientist with 217 D-Index or more.

Overview

Stephen D. Nimer is affiliated with the University of Miami in the United States. Their research primarily focuses on medicine, with a substantial number of publications in biochemistry, genetics, and molecular biology. Within these fields, their work concentrates on molecular biology, hematology, immunology, genetics, and cancer research.

The main topics covered by their research include acute myeloid leukemia, epigenetics and DNA methylation, myeloproliferative neoplasms diagnosis and treatment, cancer-related gene regulation, cancer genomics and diagnostics, histone deacetylase inhibitors, and multiple myeloma research and treatments.

Several notable papers published by Stephen D. Nimer illustrate the scope and focus of their research:

  • HOXBLINC long non-coding RNA activation promotes leukemogenesis in NPM1-mutant acute myeloid leukemia, 2021, Nature Communications
  • RAC1 plays an essential role in estrogen receptor alpha function in breast cancer cells, 2021, Oncogene
  • Acute Myeloid Leukemia iPSCs Reveal a Role for RUNX1 in the Maintenance of Human Leukemia Stem Cells, 2020, Cell Reports
  • SETD2 deficiency accelerates MDS-associated leukemogenesis via S100a9 in NHD13 mice and predicts poor prognosis in MDS, 2020, Blood
  • Tracking the Evolution of Therapy-Related Myeloid Neoplasms Using Chemotherapy Signatures, 2023, Blood

The venues where Stephen D. Nimer has frequently published include Blood, bioRxiv (Cold Spring Harbor Laboratory), Cell Reports, Nature Communications, and Leukemia. Blood stands out as the venue with the highest number of publications.

  • Blood
  • bioRxiv (Cold Spring Harbor Laboratory)
  • Cell Reports
  • Nature Communications
  • Leukemia

Frequent collaborators in their research efforts include Justin Taylor, Mikkael A. Sekeres, Daniel Bilbao, Jun Sun, and Na Man. These coauthors have contributed to multiple projects alongside Stephen D. Nimer, reflecting sustained research partnerships.

  • Justin Taylor
  • Mikkael A. Sekeres
  • Daniel Bilbao
  • Jun Sun
  • Na Man

Best Publications

  • Decitabine improves patient outcomes in myelodysplastic syndromes: results of a phase III randomized study.

    Hagop Kantarjian;Jean-Pierre J. Issa;Craig S. Rosenfeld M.D.;John M. Bennett

  • Clinical application and proposal for modification of the International Working Group (IWG) response criteria in myelodysplasia

    Bruce D. Cheson;Peter L. Greenberg;John M. Bennett;Bob Lowenberg

  • Tet2 loss leads to increased hematopoietic stem cell self-renewal and myeloid transformation.

    Kelly Moran-Crusio;Linsey Reavie;Alan Shih;Omar Abdel-Wahab

  • Report of an international working group to standardize response criteria for myelodysplastic syndromes

    B. D. Cheson;J. M. Bennett;Hagop M Kantarjian;A. Pinto

  • Patients with acute myeloid leukemia and an activating mutation in FLT3 respond to a small-molecule FLT3 tyrosine kinase inhibitor, PKC412

    Richard M. Stone;Daniel J. DeAngelo;Virginia Klimek;Ilene Galinsky

  • ASXL1 mutations promote myeloid transformation through loss of PRC2-mediated gene repression.

    Omar Abdel-Wahab;Mazhar Adli;Lindsay M. LaFave;Jie Gao

  • Phase IIB trial of oral midostaurin (PKC412), the FMS-like tyrosine kinase 3 receptor (FLT3) and multi-targeted kinase inhibitor, in patients with acute myeloid leukemia and high-risk myelodysplastic syndrome with either wild-type or mutated FLT3

    Thomas Fischer;Richard M. Stone;Daniel J. DeAngelo;Ilene Galinsky

  • p53 Regulates Hematopoietic Stem Cell Quiescence

    Yan Liu;Shannon E. Elf;Yasuhiko Miyata;Goro Sashida

  • A 2-step comprehensive high-dose chemoradiotherapy second-line program for relapsed and refractory Hodgkin disease: analysis by intent to treat and development of a prognostic model

    Craig H. Moskowitz;Stephen D. Nimer;Andrew D. Zelenetz;Tania Trippett

  • Rituximab and ICE as second-line therapy before autologous stem cell transplantation for relapsed or primary refractory diffuse large B-cell lymphoma

    Tarun Kewalramani;Andrew D. Zelenetz;Stephen D. Nimer;Carol Portlock

  • Ifosfamide, Carboplatin, and Etoposide: A Highly Effective Cytoreduction and Peripheral-Blood Progenitor-Cell Mobilization Regimen for Transplant-Eligible Patients With Non-Hodgkin's Lymphoma

    Craig H. Moskowitz;Joseph R. Bertino;Jill R. Glassman;Eric E. Hedrick

  • Primary myelofibrosis (PMF), post polycythemia vera myelofibrosis (post-PV MF), post essential thrombocythemia myelofibrosis (post-ET MF), blast phase PMF (PMF-BP): Consensus on terminology by the international working group for myelofibrosis research and treatment (IWG-MRT).

    Ruben A. Mesa;Srdan Verstovsek;Francisco Cervantes;Giovanni Barosi

  • Heterodimeric JAK–STAT activation as a mechanism of persistence to JAK2 inhibitor therapy

    Priya Koppikar;Neha Bhagwat;Outi Kilpivaara;Taghi Manshouri

  • Enhancement of ligand-dependent activation of human natural killer T cells by lenalidomide: therapeutic implications

    David H. Chang;Nancy Liu;Nancy Liu;Virginia Klimek;Virginia Klimek;Hani Hassoun;Hani Hassoun

  • NCCN Clinical Practice Guidelines in Oncology: myelodysplastic syndromes

    Greenberg Pl;Attar E;Bennett Jm;Bloomfield Cd

  • Age-adjusted International Prognostic Index predicts autologous stem cell transplantation outcome for patients with relapsed or primary refractory diffuse large B-cell lymphoma

    Paul A. Hamlin;Andrew D. Zelenetz;Tarun Kewalramani;Jing Qin

  • Transforming growth factor β-induced cell cycle arrest of human hematopoietic cells requires p57KIP2 up-regulation

    Joseph M. Scandura;Piernicola Boccuni;Joan Massagué;Joan Massagué;Stephen D. Nimer

  • Clinical resistance to the kinase inhibitor PKC412 in acute myeloid leukemia by mutation of Asn-676 in the FLT3 tyrosine kinase domain

    Florian Heidel;Fian K. Solem;Frank Breitenbuecher;Daniel B. Lipka

  • JAK2V617F-Mediated Phosphorylation of PRMT5 Downregulates Its Methyltransferase Activity and Promotes Myeloproliferation

    Fan Liu;Xinyang Zhao;Fabiana Perna;Lan Wang

  • Heterodimeric JAK-STAT Activation As a Mechanism of Persistence to JAK2 Inhibitor Therapy

    Neha Bhagwat;Priya Koppikar;Outi Kilpivaara;Taghi Manshouri

Frequent Co-Authors

Craig H. Moskowitz
Craig H. Moskowitz University of Miami
Andrew D. Zelenetz
Andrew D. Zelenetz Memorial Sloan Kettering Cancer Center
Julie Teruya-Feldstein
Julie Teruya-Feldstein Icahn School of Medicine at Mount Sinai
Madhav V. Dhodapkar
Madhav V. Dhodapkar Emory University
Suresh C. Jhanwar
Suresh C. Jhanwar Memorial Sloan Kettering Cancer Center
Ross L. Levine
Ross L. Levine Memorial Sloan Kettering Cancer Center
Gary J. Schiller
Gary J. Schiller University of California, Los Angeles
Joachim Yahalom
Joachim Yahalom Memorial Sloan Kettering Cancer Center
Richard E. Champlin
Richard E. Champlin The University of Texas MD Anderson Cancer Center
Judith C. Gasson
Judith C. Gasson University of California, Los Angeles

If you think any of the details on this page are incorrect, let us know.

Report an issue

We appreciate your kind effort to assist us to improve this page, it would be helpful providing us with as much detail as possible in the text box below:

Related Online Degrees & Career Pathways

Studying Medicine in the USA opens the door to diverse online degrees and career pathways, especially in the growing field of nursing. Many students now choose flexible, online options to advance their education and careers while balancing work or family commitments.

If you're aiming to become a Registered Nurse quickly and affordably, cheapest online accelerated BSN programs provide a fast-track route to enter the nursing workforce. For registered nurses looking to expand their qualification and earning potential, the cheapest RN to BSN programs enable you to earn your Bachelor of Science in Nursing fully online at a lower cost.

Non-nurses with a bachelor’s degree in another field can consider direct entry MSN programs online, which offer a seamless transition into advanced nursing careers. For those seeking leadership, education, or research roles, online nursing PhD programs deliver rigorous training at the doctoral level with the flexibility of distance learning.

Each pathway offers unique opportunities—whether entering healthcare for the first time or advancing to higher-level positions—making it easier than ever to chart your own course in medicine and nursing.

Best Scientists Citing Stephen D. Nimer

Trending Scientists

Recently Published Articles